Stockscreener 앱 받기
2.95
4.53%
-0.14
시간 외 거래:
2.95
Ac Immune Sa 주식(ACIU)의 최신 뉴스
ACIU Unveils Promising Phase 1 Data for TDP-43 PET Imaging - GuruFocus
AC Immune shows first brain images of TDP-43 pathology in trial - Investing.com
AC Immune Presents First In vivo Images of Brain TDP-43 - GlobeNewswire
Aug Volume: Does AC Immune SA outperform in volatile markets2026 Price Momentum & Growth Oriented Trading Recommendations - baoquankhu1.vn
AC Immune (ACIU) CFO discloses common shares, RSUs and option grants - Stock Titan
AC Immune (NASDAQ: ACIU) director Monika Buetler details initial share and option holdings - Stock Titan
AC Immune (NASDAQ: ACIU) director reports initial Form 3 holdings - Stock Titan
[Form 3] AC Immune SA Initial Statement of Beneficial Ownership - Stock Titan
AC Immune (ACIU) CEO discloses equity and option holdings - Stock Titan
AC Immune (ACIU) director June Carl Howard details share and option stakes - Stock Titan
AC Immune (ACIU) Upgraded to Buy: Here's Why - Yahoo Finance
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year? - Yahoo Finance
FY2026 EPS Estimates for AC Immune Lifted by HC Wainwright - MarketBeat
Trend Review: Will AC Immune SA outperform its industry peersWeekly Earnings Recap & Growth Oriented Trading Recommendations - baoquankhu1.vn
ACIU: BTIG Reiterates Buy Rating with $8 Target Price | ACIU Sto - GuruFocus
AC Immune: Advancing Neurology Pipeline and Imminent Alzheimer’s Vaccine Data Support Buy Rating - TipRanks
Jefferies Maintains Buy on ACIU (AC Immune S.A.) March 2026 - Meyka
AC Immune (ACIU) Loss Of CHF 15.9 Million Tests Bullish Profitability Narratives - simplywall.st
Jefferies reiterates AC Immune stock Buy rating on vaccine data By Investing.com - Investing.com Australia
Jefferies reiterates AC Immune stock Buy rating on vaccine data - Investing.com
AC Immune 2025 Financials: Annual Loss of $85M, Q4 Revenue $423KNews and Statistics - IndexBox
AC Immune Posts 2025 Results, Sharpens Pipeline Focus and Extends Cash Runway to 2027 - TipRanks
ACIU: Positive interim results for ACI-7104 and strategic focus extend cash runway to Q3 2027 - TradingView
AC Immune reports FY25 EPS (CHF 0.70) vs (CHF 0.51) last year - TipRanks
AC Immune: Fourth Quarter Financial Results Overview - Bitget
AC Immune: Q4 Earnings Snapshot - Barchart
ACIU: Net loss increased to CHF 70.4 million in 2025 as revenue declined and R&D costs remained high - TradingView
AC Immune (NASDAQ: ACIU) posts 2025 loss but flags key 2026 trial milestones - Stock Titan
Parkinson’s trial hints AC Immune vaccine may slow disease - Stock Titan
AC Immune (ACIU) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
AC Immune SA expected to post a loss of 17 rappen a shareEarnings Preview - TradingView
Risk Report: What is AC Immune SAs book value per shareJuly 2025 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Aug Big Picture: Should I buy AC Immune SA stock nowJuly 2025 Patterns & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Hedge Fund Bets: What is the long term forecast for AC Immune SA stockJuly 2025 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 - GlobeNewswire
Inside a 2026 push to prevent Parkinson’s at AC Immune’s symposium - Stock Titan
AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Will AC Immune SA stock hit new highs in YEAR2025 Historical Comparison & Risk Controlled Swing Alerts - baoquankhu1.vn
AC Immune (ACIU) Begins Phase 1 Trial for New Inflammation Treat - GuruFocus
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor - Investing.com Nigeria
AC Immune Doses First Participant in Phase 1 Trial of NLRP3 Inhibitor ACI-19764 - TipRanks
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor By Investing.com - Investing.com South Africa
AC Immune (NASDAQ: ACIU) begins Phase 1 test of NLRP3 inhibitor ACI-19764 - Stock Titan
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor - The Manila Times
Can AC Immune SA deliver consistent EPS growthMarket Volume Report & Community Verified Trade Signals - mfd.ru
ACIU Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aug EndMonth: Can AC Immune SA deliver consistent EPS growthTrade Volume Report & Entry and Exit Point Strategies - baoquankhu1.vn
J&J Pauses Enrollment In Trial Of AC Immune-Partnered Anti-Tau Immunotherapy - Citeline News & Insights
AC Immune Says Recruitment Temporarily Paused in Ongoing Study for Alzheimer's Disease Treatment - marketscreener.com
Is AC Immune SA stock a buy before product launchesMarket Growth Review & Advanced Swing Trade Entry Alerts - mfd.ru
AC Immune (ACIU) Faces Enrollment Pause in Alzheimer's Trial wit - GuruFocus
AC Immune Says Janssen Pauses Enrollment in Alzheimer’s Trial but Confirms Cash Runway to Q3 2027 - TipRanks
AC Immune SA announces voluntary suspension of recruitment for its Phase II clinical trial (code-named Retain) for Alzheimer's disease treatment - Bitget
AC Immune (NASDAQ: ACIU) details Alzheimer’s trial pause and 2027 cash runway - Stock Titan
1.20%
0.06%
자본화:
|
볼륨(24시간):